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per hospital is 105 with 81% among three models: Abbott Life-
care 4100 PCA Plus II, Baxter Health care PCA II, and Baxter
Ipump Pain Management System. Average pump life is 7.7 years.
Sixty-nine percent of hospitals use only one pump model.
Approximately 92% of hospitals own most (93%) of their
pumps. The mean and median pump utilization rates are 68%
and 78%, respectively (n = 9 hospitals). Fifty-four percent of hos-
pitals use both pre-ﬁlled reservoirs (PFR) and staff-ﬁlled reser-
voirs (SFR); 31% use only SFR, and 15% use only PFR. For PFR,
69% of hospitals use morphine, 54% use meperidine, 23% use
hydromorphone, and 8% use fentanyl. For SFR, 77% use hydro-
morphone, 39% use fentanyl, 31% use morphine, and 15% use
meperidine. Hospitals store pumps in multiple locations, with
77% storing them in nursing units, 69% in recovery rooms, 54%
in central supply, 23% in operating rooms, and 15% in phar-
macies, adding to the complexity of IV PCA management. Reser-
voirs also are stored in multiple locations, with 100% of
hospitals storing them in nursing units, 85% in recovery rooms,
31% in operating rooms, and 23% in satellite pharmacies.
Transportation of pump and analgesia from storage to patient
takes approximately 5.7 and 7.6 minutes, respectively. CON-
CLUSIONS: The results of this interim analysis suggest hospital
IV PCA pump logistics vary widely and may signiﬁcantly affect
economics of IV PCA.
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Drugs containing Acetaminophen as a single active ingredient are
included in the list of over-the-counter (OTC) drugs allowed to
be sold in non-pharmacy stores in Israel beginning mid-2005. In
an event of severe overdose, Acetaminophen may cause severe
liver damage, which may result death if not treated urgently.
OBJECTIVE: 1) To examine the knowledge and perception of
parents to children and adolescents regarding the safety, adverse
effects and toxicity of Acetaminophen OTC preparations; and
2)To compare this knowledge to scientiﬁc facts from medical lit-
erature and the experience of leading pediatricians and clinical
pharmacologists. METHODS: 1) Interviews of four leading
Pediatricians/Clinical pharmacologists; and 2) A survey of 193
parents, which took place in three emergency pediatric clinics of
“Maccabi Healthcare Services” (HMO) in central Israel and
among non-medical headquarters staff. The answers were
processed using statistical software. Inﬂuences of several demo-
graphic factors on parents’ answers were examined. RESULTS:
In total, 65% of the enrolled parents had the perception that
non-prescription drugs might be harmful if not used properly,
while 55% of them thought that Acetaminophen might be
harmful if not used properly. In the higher education group more
parents thought that Acetaminophen had had adverse effects.
Higher proportion of parents of two or more children felt they
had knew how to use Acetaminophen brands properly compared
to parents of one child. More than 60% of the parents reported
that they usually purchase Acetaminophen brands without a pre-
scription. About 80% read the patient’s insert. CONCLUSIONS:
Enrolled parents perceive Acetaminophen brands to be safer than
the average non-prescription drug, even though it is known that
in an event of over-dosage Acetaminophen is more toxic than
most other non-prescription drugs. More educated parents in the
survey sample were more aware of the dangers of improper use
of Acetaminophen.
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OBJECTIVES: Although isolated case reports have documented
operator programming errors associated with intravenous
patient-controlled analgesia (IV PCA) infusion pumps, no sys-
tematic analysis of IV PCA-associated problems has been per-
formed. The objective of this study was to use the Manufacturer
and User Facility Device Experience (MAUDE) database, a large
publicly available database maintained by the US Food and Drug
Administration (FDA), to characterize the types of problems
associated with the use of IV PCA infusion pumps. METHODS:
We extracted all IV PCA-related MAUDE case reports from
January, 2002 through December, 2003. Reported causes of
events were abstracted and classiﬁed as: possible operator errors
(eg, pump programming errors); possible patient-related events
(eg, patient tampering), possible device-related events (eg, device
malfunctions), possible adverse drug reactions, and indetermi-
nate events (unspeciﬁed causes). RESULTS: We found 2009
unique IV PCA-related reported events. Number of events
increased from 455 in 2002 to 1554 in 2003, although the FDA
instituted no corresponding changes in reporting requirements
or data collection during these two years. Among all IV PCA-
related reports, 79.1% (N = 1590) were possible device-related
events, 6.5% (N = 131) were possible operator errors, 1.2% (N
= 25) possible adverse drug reactions, 0.6% (N = 12) possible
patient-related events, and 12.6% (N = 251) were indeterminate
events. The device manufacturer conﬁrmed 61% of the reported
possible device-related events. CONCLUSIONS: Previously pub-
lished single case reports of problems with IV PCA infusion
pumps highlight operator error. Our analysis of the MAUDE
data suggests, however, that nearly 80% of reported problems
were attributable to possible device-related events. Although
reporting bias may contribute to the high rates of possible device-
related events (ie, operator errors may be reported as device-
related events), more than half of the possible device-related
malfunctions were conﬁrmed upon manufacturer inspection. To
our knowledge, this is the ﬁrst study to use a large, retrospective
database to examine IV PCA-related problems.
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OBJECTIVES: Dose increases during long-term therapy with
strong opioids have often been reported and result from deteri-
oration of the primary disease or from tolerance development.
The purpose of this study was to compare drug utilization 
patterns with regard to dose changes of transdermal (TD) fen-
tanyl and TD buprenorphine in cancer and non-cancer patients.
METHODS: Retrospective analysis of the “IMS Disease 
Analyzer—mediplus” database which provided data from 400
general practices in Germany. An evaluation according to a pre-
vious peer-reviewed study showed that patients on long-term
treatment (three months and longer) with TD fentanyl or TD
buprenorphine had received similar analgesic pre-medication
